Evidence map›Paper›PMID 39618284›Full record

ArticleCancer discovery2024

Characterization of Persister Cells Provides Insights into Mechanisms of Therapy Resistance in Neuroblastoma.

Amber B Wolf, C Patrick Reynolds, Eveline Barbieri

Abstract read
In one paragraph

Article in Cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amber B WolfDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-4637-051X
C Patrick ReynoldsCancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.ORCID 0000-0002-2827-8536
Eveline BarbieriDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-4368-1451

Funding

Rewired Metabolism and Immunosuppression in MYCN-driven NeuroblastomaR01CA283369 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Eveline Barbieri · 2024 to 2026
$2.1M
Towards Novel Differentiation Therapies for Neuroblastoma.R01CA222224 · NCI · BAYLOR COLLEGE OF MEDICINE · PI BARBIERI, EVELINE · 2019 to 2024
$1.7M
NCI NIH HHS R01 CA222224NCI NIH HHS R01 CA283369
6 · The paper itself

Abstract

The study by Grossmann and colleagues uses single-nucleus RNA sequencing in a cohort of matched high-risk neuroblastoma primary tumor samples, obtained from the same patient at diagnosis and definitive surgery, to identify persister cells that survive induction chemotherapy. These persister cells utilize mechanisms of chemoresistance that are both tumor-intrinsic and tumor-extrinsic, are highly dependent on the original genetic profile of the tumor, and represent novel, patient-specific targets to precisely inhibit chemoresistance and disease recurrence. See related article by Grossmann et.al., p. 2387.

Indexed as

Drug Resistance, NeoplasmNeuroblastomaHumans

Identifiers

PMID39618284
PMCPMC13265036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.